NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

癌症單株抗體的全球市場:2019年∼2026年

Global Cancer Monoclonal Antibodies Market - 2019-2026

出版商 DataM Intelligence 商品編碼 968944
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
癌症單株抗體的全球市場:2019年∼2026年 Global Cancer Monoclonal Antibodies Market - 2019-2026
出版日期: 2020年09月30日內容資訊: 英文 190 Pages
簡介

全球癌症單株抗體市場,從2020年到2027年預計以11.86%的年複合成長率繼續成長。

市場擴大的原動力,是癌症患者的發生率,基因研究的投資擴大,只以癌症細胞為目標的單株抗體出色的特性等要素。另一方面,先進技術開發需要的高額費用,各國的藥事法規方面的問題等,有成為市場擴大障礙的可能性。

本報告提供全球癌症單株抗體市場調查,市場趨勢,產業分析,產品分析,各地區的分析,競爭情形,企業簡介等資訊。

目錄

第1章 調查手法和範圍

第2章 市場趨勢

第3章 產業分析

  • 影響產業的要素(推動要素與法規)
  • 競爭情形:波特的五力分析
  • 法規分析

第4章 產品分析

  • 各產品
    • 人體化抗體
    • 小鼠抗體
    • 嵌合抗體
    • 人類抗體
    • 老鼠抗體
    • 免疫毒素
    • 免疫粘附素
    • 其他
  • 各用途
    • 非小細胞肺癌
    • 結腸直腸癌症
    • 乳癌
    • 前列腺癌症
    • 血液癌症
    • 神經膠質瘤癌症
    • 膀胱癌
    • 淋巴瘤
    • 卵巢癌症
    • 其他

第5章 地區市場分析

  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 其他地區

第6章 競爭情形

  • 市場佔有率分析
  • 主要策略
  • 產品的基準

第7章 企業簡介

  • ImmunoGen Inc.
  • Spectrum Pharmaceuticals
  • Amgen Inc.
  • Lifeline Scientific
  • Bristol-Meyer Squibb
  • GlaxoSmithKline
  • Roche Holding
  • Merck & Co. Inc.
  • Seattle Genetics
  • Novartis AG

第8章 附錄

目錄

Market Overview

The Global Cancer Monoclonal Antibodies market is expected to grow at a CAGR of 11.86% during the forecast period (2020-2027).

Monoclonal Antibodies are mono-specific antibodies bodies having identical immune cells which are clones of a single parent cell and are directed to specific cellular targets. Therefore, Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. Hence, monoclonal antibodies technology is proved to be more effective than other cancer therapies.

Market Dynamics

The market growth is driven by several factors such as the rising incidence of cancer patients and growing investments by the companies in the research and development of genomic studies. The market is also driven by the specificity of the nature of monoclonal antibodies to target only cancer cells. However, the market is negatively affected by the high costs involved in the development of these advanced techniques and regulatory issues faced by the countries for the rolling out of these products.

The largest part of cancer immunotherapies involved monoclonal antibodies as monoclonal antibodies having more potential to offer less toxic and efficient therapy to the patients. They are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer.

Market Segmentation

Based on antibodies, the market is segmented into Humanized, Murine, Rat, Chimeric, Human, Immunotoxin, Immunoadhesin, and Others.

Based on Applications, the market is segmented into Non-small-cell lung cancers, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, Glioma cancer, Bladder Cancer, Lymphoma, Ovarian Cancer, and Others.

Geographical Analysis

Geographically, the market is segmented into North America, South America, Europe, Asia-Pacific, and RoW.

North America dominates the global cancer monoclonal antibodies market due to the well-established healthcare infrastructures, increased spending by the government for infection control and management, and the rising prevalence of lifestyle-related diseases.

In 2015, the US government spent US 13.6 billion to execute the above-mentioned activities. This region is expected to show growth owing to the rise in funding by the government for cancer research and technology development.

Market Key Companies

The global Cancer Monoclonal Antibodies market share is divided majorly among ImmunoGen Inc, Spectrum Pharmaceuticals, Amgen Inc, Lifeline Scientific, Bristol-Meyer Squibb, GlaxoSmithKline, Roche Holding, Merck & Co. Inc., Seattle Genetics, and Novartis AG.

The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.

Key takeaways from this report

Visualize the composition of the Global Cancer Monoclonal Antibodies market across each indication, in terms of type and applications, highlighting the key commercial assets and players.

Identify commercial opportunities in Global Cancer Monoclonal Antibodies by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of the Global Cancer Monoclonal Antibodies market - level 4/5 segmentation

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study

Product mapping in excel for the key Global Cancer Monoclonal Antibodies products of all major market players.

Table of Contents

1. Cancer Monoclonal Antibodies market - Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Scope of the Report

2. Global Cancer Monoclonal Antibodies Market -Trends

  • 2.1. Key Trends & Developments

3. Global Cancer Monoclonal Antibodies Market - Industry Analysis

  • 3.1. Industry Impact Factors (Drivers & Restraints)
  • 3.2. Competitive Intensity- Porter 5 Forces
  • 3.3. Regulatory Analysis

4. Global Cancer Monoclonal Antibodies Market- Product Analysis

  • 4.1. Cancer Monoclonal Antibodies Market - By Monoclonal Antibodies
    • 4.1.1. Humanized
    • 4.1.2. Murine
    • 4.1.3. Chimeric
    • 4.1.4. Human
    • 4.1.5. Rat
    • 4.1.6. Immunotoxin
    • 4.1.7. Immunoadhesin
    • 4.1.8. Others
  • 4.2. Cancer Monoclonal Antibodies Market - By Applications
    • 4.2.1. Non-small-cell lung cancers
    • 4.2.2. Colorectal Cancer
    • 4.2.3. Breast Cancer
    • 4.2.4. Prostate Cancer
    • 4.2.5. Blood Cancer
    • 4.2.6. Glioma cancers
    • 4.2.7. Bladder Cancer
    • 4.2.8. Lymphoma
    • 4.2.9. Ovarian Cancer
    • 4.2.10. Others

5. Global Cancer Monoclonal Antibodies Market- Geographical Analysis

  • 5.1. Asia Pacific
    • 5.1.1. China
    • 5.1.2. Japan
    • 5.1.3. India
    • 5.1.4. Australia
    • 5.1.5. Rest of Asia Pacific
  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. The UK
    • 5.2.4. Italy
    • 5.2.5. Spain
    • 5.2.6. Rest of Europe
  • 5.3. North America
    • 5.3.1. The USA
    • 5.3.2. Canada
    • 5.3.3. Mexico
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
    • 5.4.3. Rest of South America
  • 5.5. RoW

6. Global Cancer Monoclonal Antibodies Market - Competitive Landscape

  • 6.1 Market Share Analysis
  • 6.2 Key Strategies
  • 6.3 Product Benchmarking

7. Global Cancer Monoclonal Antibodies Market - Company Profiles

  • 7.1 ImmunoGen Inc.
  • 7.2 Spectrum Pharmaceuticals
  • 7.3 Amgen Inc.
  • 7.4 Lifeline Scientific
  • 7.5 Bristol-Meyer Squibb
  • 7.6 GlaxoSmithKline
  • 7.7 Roche Holding
  • 7.8 Merck & Co. Inc.
  • 7.9 Seattle Genetics
  • 7.10 Novartis AG

8. Global Cancer Monoclonal Antibodies Market - Appendix

  • 8.1 Sources
  • 8.2 List of Tables
  • 8.3 Expert Panel Validation
  • 8.4 Disclaimer
  • 8.5 Contact Us